Synthesis, 68Ga-radiolabeling, and preliminary in vivo assessment of a depsipeptide-derived compound as a potential PET/CT infection imaging agent

dc.contributor.authorMokaleng, Botshelo B.
dc.contributor.authorEbenhan, Thomas
dc.contributor.authorRamesh, Suhas
dc.contributor.authorGovender, Thavendran
dc.contributor.authorKruger, Hendrik G.
dc.contributor.authorParboosing, Raveen
dc.contributor.authorHazari, Puja P.
dc.contributor.authorMishra, Anil K.
dc.contributor.authorMarjanovic-Painter, Biljana
dc.contributor.authorZeevaart, Jan Rijn
dc.contributor.authorSathekge, Mike Machaba
dc.contributor.emailmike.sathekge@up.ac.zaen_ZA
dc.date.accessioned2015-12-11T05:33:48Z
dc.date.available2015-12-11T05:33:48Z
dc.date.issued2015
dc.description.abstractNoninvasive imaging is a powerful tool for early diagnosis and monitoring of various disease processes, such as infections. An alarming shortage of infection-selective radiopharmaceuticals exists for overcoming the diagnostic limitations with unspecific tracers such as 67/68Ga-citrate or 18F-FDG. We report here TBIA101, an antimicrobial peptide derivative that was conjugated to DOTA and radiolabeled with 68Ga for a subsequent in vitro assessment and in vivo infection imaging using Escherichia coli-bearing mice by targeting bacterial lipopolysaccharides with PET/CT. Following DOTA-conjugation, the compound was verified for its cytotoxic and bacterial binding behaviour and compound stability, followed by 68Gallium-radiolabeling. µPET/CT using 68Ga-DOTA-TBIA101 was employed to detect muscular E. coli-infection in BALB/c mice, as warranted by the in vitro results. 68Ga-DOTA-TBIA101-PET detected E. coli-infected muscle tissue (SUV = 1.3–2.4) > noninfected thighs (P = 0.322) > forearm muscles (P = 0.092) > background (P = 0.021) in the same animal. Normalization of the infected thigh muscle to reference tissue showed a ratio of 3.0 ± 0.8 and a ratio of 2.3 ± 0.6 compared to the identical healthy tissue. The majority of the activity was cleared by renal excretion. The latter findings warrant further preclinical imaging studies of greater depth, as the DOTA-conjugation did not compromise the TBIA101's capacity as targeting vector.en_ZA
dc.description.librarianhb2015en_ZA
dc.description.sponsorshipDepartment of Nuclear Medicine at the University of Pretoria. Department of Science and Technology.en_ZA
dc.description.urihttp://www.hindawi.com/journals/bmri/en_ZA
dc.identifier.citationMokaleng, BB, Ebenhan, T, Ramesh, S, Govender, T, Kruger, HG, Parboosing, R, Hazari, PP, Mishra, AK, Marjanovic-Painter, B, Zeevaart, JR & Sathekge, MM 2015, 'Synthesis, 68Ga-radiolabeling, and preliminary in vivo assessment of a depsipeptide-derived compound as a potential PET/CT infection imaging agent', BioMed Research International, vol. 2015, art. #284354, pp. 1-12.en_ZA
dc.identifier.issn2314-6133 (print)
dc.identifier.issn2314-6141 (online)
dc.identifier.other10.1155/2015/284354
dc.identifier.urihttp://hdl.handle.net/2263/51139
dc.language.isoenen_ZA
dc.publisherHindawi Publishingen_ZA
dc.rights© 2015 Botshelo B. Mokaleng et al. This is an open access article distributed under the Creative Commons Attribution License.en_ZA
dc.subjectRadiopharmaceuticalsen_ZA
dc.subjectInfectious diseasesen_ZA
dc.subjectSterile inflammationen_ZA
dc.subjectDepsidomycin-derived compoundsen_ZA
dc.subjectRadiolabelingen_ZA
dc.titleSynthesis, 68Ga-radiolabeling, and preliminary in vivo assessment of a depsipeptide-derived compound as a potential PET/CT infection imaging agenten_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Mokaleng_Synthesis_2015.pdf
Size:
1.85 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: